Background: Limited reports exist on the antemortem presumptive diagnosis and treatment of feline neurocuterebriasis. A 3-day treatment protocol reported for 3 cats had no adverse effects. This protocol comprised ivermectin (0.4 mg/kg), diphenhydramine (4 mg/kg), and dexamethasone (0.1 mg/kg) given q24h.
Objective: To describe the treatment outcomes for cats that received the 3-day ivermectin protocol and antemortem diagnostic methods used before.
Animals And Procedure: Medical records from a single veterinary referral centre were searched to identify cats treated with the 3-day protocol. Variables extracted included signalment, season, history, neurological examination findings, and advanced diagnostic tests, as well as outcomes based on follow-up.
Results: Thirteen cats were diagnosed based on advanced imaging. Ten of 13 also underwent cerebrospinal fluid analysis. Other diagnostic factors included season (July through September), signalment (young to middle-aged), lifestyle (outdoor access), history (7/13 cats showed upper respiratory signs preceding neurological deficits), and clinical signs (central neurological deficits). After being treated with the 3-day ivermectin protocol, 10/13 cats improved. Three cats were euthanized after showing worsening clinical signs.
Conclusion And Clinical Relevance: Outcomes using the 3-day ivermectin protocol appeared favorable. This provided insight about a treatment option for a periodic cause of feline encephalomyelopathy that has potential for deployment in first-opinion practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705184 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Antemortem diagnostic tests and treatment outcomes using ivermectin in 13 cases of presumptive feline neurocuterebriasis.
Can Vet J
January 2025
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario N1G 2W1.
Background: Limited reports exist on the antemortem presumptive diagnosis and treatment of feline neurocuterebriasis. A 3-day treatment protocol reported for 3 cats had no adverse effects. This protocol comprised ivermectin (0.
View Article and Find Full Text PDFMosquitocidal efficacy and pharmacokinetics of single-dose ivermectin versus three-day dose regimen for malaria vector control compared with albendazole and no treatment: An open-label randomized controlled trial.
Int J Infect Dis
November 2024
Department of Clinical Trials, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK. Electronic address:
Article Synopsis
- The study aimed to assess how different dosing regimens of ivermectin affect the survival of malaria vectors (mosquitoes) and their potential to reduce malaria transmission.
- An open-label randomized control trial was conducted in Kenya with 36 participants, comparing a single dose of ivermectin, a 3-day regimen of ivermectin, albendazole, and a control group with no treatment.
- Results indicated that both ivermectin regimens significantly impacted mosquito survival within the first week, but the single dose proved to be more effective over a 10-day period compared to the multi-day regimen.
Lack of antiviral activity of ivermectin against foot-and-mouth disease virus serotype O in BALB/c mice.
Microb Pathog
September 2023
Department of Pharmacology and Toxicology, University of Veterinary and Animal Sciences, Lahore, Pakistan.
Ivermectin is an FDA approved drug and showed in vitro antiviral activity against different serotypes of Foot-and-mouth disease virus (FMDV). We here assessed the effect of ivermectin in 12 day old female BALB/c mice infected with 50LD FMDV serotype O intraperitoneally. Initially FMDV was adopted on 3-day old BALB/c mice by blind passages.
View Article and Find Full Text PDFA Randomized Controlled Trial of Combined Ivermectin and Zinc Sulfate versus Combined Hydroxychloroquine, Darunavir/Ritonavir, and Zinc Sulfate among Adult Patients with Asymptomatic or Mild Coronavirus-19 Infection.
J Glob Infect Dis
June 2022
Department of Medical Sciences, Genomic Medicine and Innovation Support, Ministry of Public Health, Nonthaburi, Thailand.
Introduction: Ivermectin, hydroxychloroquine (HQ), and darunavir/ritonavir are widely prescribed as an oral treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection despite their uncertainty of clinical benefit. The objective is to determine the safety and the efficacies of two treatment regimens against SARS-CoV-2 infection.
Methods: We conducted an open-labeled, randomized, controlled trial to compare the efficacy between a 3-day course of once-daily high-dose oral ivermectin plus zinc sulfate (Group A) and a combination of HQ, darunavir/ritonavir, and zinc sulfate (HQ + antiretroviral, Group B) for 5 days in asymptomatic or mild SARS-CoV-2 infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!